Usana Health Sciences Return on Equity (ROE) Growth & History (USNA)
Usana Health Sciences's return on equity was 2.02% for fiscal 2025.
View full Usana Health Sciences company overviewUsana Health Sciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2026-01-03 | 2.02% | −6.15 pp |
| 2024 | 2024-12-28 | 8.17% | −5.53 pp |
| 2023 | 2023-12-30 | 13.69% | −3.03 pp |
| 2022 | 2022-12-31 | 16.72% | −11.13 pp |
| 2021 | 2022-01-01 | 27.85% | −3.58 pp |
| 2020 | 2021-01-02 | 31.43% | +4.36 pp |
| 2019 | 2019-12-28 | 27.06% | −6.40 pp |
| 2018 | 2018-12-29 | 33.47% | +15.30 pp |
| 2017 | 2017-12-30 | 18.17% | −14.84 pp |
| 2016 | 2016-12-31 | 33.01% | −4.04 pp |
| 2015 | 2016-01-02 | 37.05% | +5.82 pp |
| 2014 | 2015-01-03 | 31.24% | −4.19 pp |
| 2013 | 2013-12-28 | 35.43% | −1.53 pp |
| 2012 | 2012-12-29 | 36.96% | +5.31 pp |
| 2011 | 2011-12-31 | 31.65% | −9.63 pp |
| 2010 | 2011-01-01 | 41.28% | — |
Usana Health Sciences quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-07-04 | −4.00% | −5.82 pp |
| Q1 2026 | 2026-04-04 | 1.40% | −0.37 pp |
| Q4 2025 | 2026-01-03 | −0.33% | −1.17 pp |
| Q3 2025 | 2025-09-27 | −1.23% | −3.26 pp |
| Q2 2025 | 2025-06-28 | 1.82% | −0.24 pp |
| Q1 2025 | 2025-03-29 | 1.77% | −1.55 pp |
| Q4 2024 | 2024-12-28 | 0.84% | −2.63 pp |
| Q3 2024 | 2024-09-28 | 2.03% | −0.39 pp |
| Q2 2024 | 2024-06-29 | 2.06% | −1.68 pp |
| Q1 2024 | 2024-03-30 | 3.32% | −0.82 pp |
| Q4 2023 | 2023-12-30 | 3.47% | +0.44 pp |
| Q3 2023 | 2023-09-30 | 2.42% | −1.25 pp |
| Q2 2023 | 2023-07-01 | 3.74% | −1.09 pp |
| Q1 2023 | 2023-04-01 | 4.13% | −1.59 pp |
| Q4 2022 | 2022-12-31 | 3.03% | −2.09 pp |
| Q3 2022 | 2022-10-01 | 3.66% | −3.02 pp |
| Q2 2022 | 2022-07-02 | 4.83% | −4.48 pp |
| Q1 2022 | 2022-04-02 | 5.72% | −1.53 pp |
| Q4 2021 | 2022-01-01 | 5.12% | −4.42 pp |
| Q3 2021 | 2021-10-02 | 6.68% | −1.58 pp |
| Q2 2021 | 2021-07-03 | 9.31% | +0.92 pp |
| Q1 2021 | 2021-04-03 | 7.25% | −0.68 pp |
| Q4 2020 | 2021-01-02 | 9.54% | +0.30 pp |
| Q3 2020 | 2020-09-26 | 8.27% | +1.33 pp |
| Q2 2020 | 2020-06-27 | 8.39% | +2.88 pp |
| Q1 2020 | 2020-03-28 | 7.93% | +1.75 pp |
| Q4 2019 | 2019-12-28 | 9.24% | +1.41 pp |
| Q3 2019 | 2019-09-28 | 6.94% | −0.24 pp |
| Q2 2019 | 2019-06-29 | 5.51% | −2.65 pp |
| Q1 2019 | 2019-03-30 | 6.18% | −1.40 pp |
| Q4 2018 | 2018-12-29 | 7.82% | +9.43 pp |
| Q3 2018 | 2018-09-29 | 7.18% | +0.81 pp |
| Q2 2018 | 2018-06-30 | 8.17% | +1.86 pp |
| Q1 2018 | 2018-03-31 | 7.58% | +1.29 pp |
| Q4 2017 | 2017-12-30 | −1.61% | −8.53 pp |
| Q3 2017 | 2017-09-30 | 6.37% | −3.98 pp |
| Q2 2017 | 2017-07-01 | 6.31% | −3.62 pp |
| Q1 2017 | 2017-04-01 | 6.29% | −2.19 pp |
| Q4 2016 | 2016-12-31 | 6.91% | −1.15 pp |
| Q3 2016 | 2016-10-01 | 10.35% | +1.78 pp |
| Q2 2016 | 2016-07-02 | 9.93% | +0.48 pp |
| Q1 2016 | 2016-04-02 | 8.48% | +0.34 pp |
| Q4 2015 | 2016-01-02 | 8.07% | −1.85 pp |
| Q3 2015 | 2015-10-03 | 8.57% | −0.03 pp |
| Q2 2015 | 2015-07-04 | 9.45% | +2.22 pp |
| Q1 2015 | 2015-04-04 | 8.14% | +2.02 pp |
| Q4 2014 | 2015-01-03 | 9.92% | +1.79 pp |
| Q3 2014 | 2014-09-27 | 8.60% | +1.19 pp |
| Q2 2014 | 2014-06-28 | 7.23% | −4.83 pp |
| Q1 2014 | 2014-03-29 | 6.12% | −3.41 pp |
| Q4 2013 | 2013-12-28 | 8.13% | −1.52 pp |
| Q3 2013 | 2013-09-28 | 7.40% | −1.79 pp |
| Q2 2013 | 2013-06-29 | 12.06% | +3.12 pp |
| Q1 2013 | 2013-03-30 | 9.53% | +1.99 pp |
| Q4 2012 | 2012-12-29 | 9.64% | +1.74 pp |
| Q3 2012 | 2012-09-29 | 9.19% | +1.26 pp |
| Q2 2012 | 2012-06-30 | 8.94% | −0.30 pp |
| Q1 2012 | 2012-03-31 | 7.54% | — |
| Q4 2011 | 2011-12-31 | 7.90% | — |
| Q3 2011 | 2011-10-01 | 7.93% | — |
| Q2 2011 | 2011-07-02 | 9.24% | — |
Usana Health Sciences return on equity trends
Over the last five fiscal years, Usana Health Sciences's return on equity decreased from 31.43% to 2.02%, a change of −29.41 percentage points. The latest reported quarter, Q2 2026, shows −4.00%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Usana Health Sciences source filings ↗